MAGE-C1 Antibody (G-6): sc-514630

MAGE-C1 Antibody (G-6) is a mouse monoclonal IgG2a antibody that detects MAGE-C1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MAGE-C1, also known as CT7, is a member of the melanoma-associated antigen (MAGE) family, which is primarily recognized for its role in tumor rejection and expression in various tumors, particularly in multiple myeloma, where MAGE-C1 correlates with plasma-cell proliferation. The significance of MAGE-C1 lies not only in tumor-specific expression but also in potential as a target for cancer immunotherapy, given that MAGE genes are largely absent in normal tissues, with the exception of the testis and placenta. Understanding MAGE-C1 structure is crucial, as a unique domain allows for interaction with specific immune receptors, facilitating the activation of cytotoxic T lymphocytes. This interaction is vital for the immune system′s ability to recognize and eliminate cancer cells, making MAGE-C1 a promising candidate for therapeutic strategies aimed at enhancing anti-tumor immunity. anti-MAGE-C1 antibody (G-6) provides researchers with a powerful tool to explore MAGE-C1′s role in cancer biology and potential applications in immunotherapy.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MAGE-C1 Antibody (G-6) References:

1. MAGE-C1 (CT7) gene expression in multiple myeloma: relationship to sperm protein 17.  |  Lim, SH., et al. 2001. Eur J Haematol. 67: 332-4. PMID: 11872084
2. CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues.  |  Jungbluth, AA., et al. 2002. Int J Cancer. 99: 839-45. PMID: 12115486
3. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).  |  Cho, HJ., et al. 2006. Cancer Immun. 6: 12. PMID: 17137291
4. Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility.  |  Krüger, S., et al. 2007. Pathol Oncol Res. 13: 91-6. PMID: 17607369
5. MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma.  |  Curioni-Fontecedro, A., et al. 2008. Leukemia. 22: 1646-8. PMID: 18323799
6. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.  |  Lendvai, N., et al. 2010. Cancer Immun. 10: 4. PMID: 20108890
7. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.  |  Nuber, N., et al. 2010. Proc Natl Acad Sci U S A. 107: 15187-92. PMID: 20696919
8. Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.  |  Pagotto, A., et al. 2013. PLoS One. 8: e83212. PMID: 24340093
9. The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance.  |  Hou, S., et al. 2016. Am J Surg. 211: 142-51. PMID: 26321295
10. High expression of MAGE-C1 gene in colorectal cancer is associated with its poor prognosis.  |  Tian, Y., et al. 2021. J Gastrointest Oncol. 12: 2872-2881. PMID: 35070414

The preferred MAGE-C1 antibody is MAGE-C1 Antibody (CT7-33): sc-53868.